Learn More
Studies of histone deacetylase (HDAC) inhibitors, novel anticancer drugs, in models of autoimmune diseases, asthma, and inflammatory bowel disease suggest that HDAC inhibitors may also have useful anti-inflammatory effects. Accordingly, in vitro studies relevant to asthma and inflammatory bowel disease were conducted using a selection of HDAC inhibitors:(More)
Syntheses of aryloxyalkanoic acid hydroxyamides are described, all of which are potent inhibitors of histone deacetylase, some being more potent in vitro than trichostatin A (IC(50)=3 nM). Variation of the substituents on the benzene ring as well as fusion of a second ring have marked effects on potency, in vitro IC(50) values down to 1 nM being obtained.
Among histone deacetylase inhibitors (HDACis) are found novel anticancer drugs, and compounds that exhibit anti-inflammatory effects[1], although detailed mode of action of the latter is unknown. Accordingly, we have studied the effects of suberoylanilide hydroxamic acid (SAHA), a related branched hydroxamic acid, 2-phenylcarbamoyloctanedioic acid(More)
Histone deacetylase inhibitors (HDACis) are promising anticancer agents, as suggested by the clinical efficacy, tolerance and safety of lead drugs [1]. HDACis also have anti-inflammatory effects in a variety of experimental models of human disease, including a mouse asthma model [2–4]. We have thus examined here the effect of these agents on antigenand(More)
  • 1